MedWatch

Investors react to Lundbeck's failed Vyepti study, analyst says uncertainty has increased

Lundbeck’s second quarterly report brought news on Wednesday that a Vyepti study in China had not panned out as hoped.

Photo: Jens Dresling

Despite the release of Lundbeck’s generally solid second quarter report on Wednesday, cementing last week’s guidance upgrade, the immediate market reaction hasn’t been all that positive.

The reason why, according to Sydbank analyst Søren Løntoft Hansen, is the announcement of a failed study in China of the company’s great growth hope, Vyepti, a preventive migraine treatment.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs